NFAT5 supports the reconstitution of hematopoietic progenitors after γ irradiation or treatment with 5-FU. (A) Number of bone marrow (n = 18 mice) and LSK cells (n = 7 mice) per mouse from WT (Nfat5^+/+ Vav-Cre) or hematopoietic cell–specific NFAT5-deficient (Nfat5^fl/fl Vav-Cre) mice. (B) Percentage of the indicated hematopoietic stem and progenitor populations in the bone marrow of Nfat5^+/+ Vav-Cre or Nfat5^fl/fl Vav-Cre mice. n = 20 to 21 mice of each genotype in the left panel, and 11 on the right. (C-D) Analysis of bone marrow from Nfat5^+/+ Vav-Cre or Nfat5^fl/fl Vav-Cre mice at 55 days after TBI (5 Gy). A schematic diagram of the experiment is shown in panel C (left). Bone marrow cellularity, number of lineage^neg, number and percentage of LSK cells (C, right), and percentage and number of hematopoietic progenitor populations (D) are shown. n = 10-17 mice of each genotype from 2 independent experiments in panel C and the left panels in panel D; n = 6-10 mice from 1 experiment in the right panels of panel D. (E-F) Analysis of bone marrow from Nfat5^+/+ Vav-Cre or Nfat5^fl/fl Vav-Cre mice treated with a regime of 3 consecutive doses of 5-FU (150 mg/kg) administered every 10 days. A schematic diagram of the experiment is shown in panel E (left). Bone marrow cellularity, number of lineage^neg, number and percentage of LSK cells (E), and percentage and number of hematopoietic progenitor populations (F) are shown. n = 5-7 mice in panels E-F. Results are shown as mean ± standard error of the mean (SEM). Statistical test: unpaired t test. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. P values < .1 are also indicated.